Cargando…

Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers

Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment. In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche. As the crosstalk between these two entities...

Descripción completa

Detalles Bibliográficos
Autores principales: Ségaliny, Aude I., Tellez-Gabriel, Marta, Heymann, Marie-Françoise, Heymann, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620971/
https://www.ncbi.nlm.nih.gov/pubmed/26579483
http://dx.doi.org/10.1016/j.jbo.2015.01.001
_version_ 1782397377234075648
author Ségaliny, Aude I.
Tellez-Gabriel, Marta
Heymann, Marie-Françoise
Heymann, Dominique
author_facet Ségaliny, Aude I.
Tellez-Gabriel, Marta
Heymann, Marie-Françoise
Heymann, Dominique
author_sort Ségaliny, Aude I.
collection PubMed
description Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment. In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche. As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed. These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours. The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases.
format Online
Article
Text
id pubmed-4620971
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-46209712015-11-17 Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers Ségaliny, Aude I. Tellez-Gabriel, Marta Heymann, Marie-Françoise Heymann, Dominique J Bone Oncol Review Article Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment. In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche. As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed. These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours. The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases. Elsevier 2015-01-23 /pmc/articles/PMC4620971/ /pubmed/26579483 http://dx.doi.org/10.1016/j.jbo.2015.01.001 Text en © 2015 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review Article
Ségaliny, Aude I.
Tellez-Gabriel, Marta
Heymann, Marie-Françoise
Heymann, Dominique
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
title Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
title_full Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
title_fullStr Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
title_full_unstemmed Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
title_short Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
title_sort receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620971/
https://www.ncbi.nlm.nih.gov/pubmed/26579483
http://dx.doi.org/10.1016/j.jbo.2015.01.001
work_keys_str_mv AT segalinyaudei receptortyrosinekinasescharacterisationmechanismofactionandtherapeuticinterestsforbonecancers
AT tellezgabrielmarta receptortyrosinekinasescharacterisationmechanismofactionandtherapeuticinterestsforbonecancers
AT heymannmariefrancoise receptortyrosinekinasescharacterisationmechanismofactionandtherapeuticinterestsforbonecancers
AT heymanndominique receptortyrosinekinasescharacterisationmechanismofactionandtherapeuticinterestsforbonecancers